---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-299177"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2026-07-09T12:05:21+00:00"
generated_at: "2026-07-09T12:10:06.895846+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences reports positive Phase 1b vitiligo results for FB102; statistically significant FVASI improvement

## Summary
- FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p=0.020) vs placebo 7.9% improvement.
- Statistically significant improvement observed by day 64 (p=0.023) and continued through week 24 after 12-week treatment.
- In subjects with baseline FVASI ≥0.75, FB102 showed 43.2% mean improvement (p=0.006); 58.8% achieved FVASI50, 23.5% FVASI75.
- 84% (27/32) of FB102-treated subjects improved from baseline to week 24; 0% worsened vs 27% of placebo worsened.
- FB102 demonstrated strong safety profile with only mild to moderate AEs, comparing favorably to placebo.

## SEC filing metadata
- accession: 0001193125-26-299177
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2026-07-09T12:05:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312526299177/0001193125-26-299177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312526299177/d170175d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-299177
- JSON: https://secwatch.observer/filing/0001193125-26-299177.json
- Plain text: https://secwatch.observer/filing/0001193125-26-299177.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.